EU/3/12/1061: Orphan designation for the treatment of idiopathic pulmonary fibrosis
Tralokinumab
Table of contents
Overview
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.
On 8 November 2012, orphan designation (EU/3/12/1061) was granted by the European Commission to MedImmune Ltd, United Kingdom, for tralokinumab for the treatment of idiopathic pulmonary fibrosis.
Key facts
Active substance |
Tralokinumab
|
Intended use |
Treatment of idiopathic pulmonary fibrosis
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/12/1061
|
Date of designation |
08/11/2012
|
Sponsor |
MedImmune Ltd
Milstein Building Granta Park Great Abington Cambridgeshire CB21 6GH United Kingdom Tel. +44 (0)1223 471 471 Fax +44 (0)1223 471 472 E-mail: tommasinii@medimmune.com |
Review of designation
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: